News

Featured News

  • 2022 |
  • 2021 |
  • 2020 |
  • 2019 |
  • 2018 |
  • 2017 |
  • View All
  • Press Release | September 10, 2022

    ImCheck Presents Positive Safety and Efficacy Data from the Completed Phase 1 Dose Escalation Cohort of ICT01 plus Pembrolizumab in the EVICTION Trial at ESMO Congress 2022

    Read More

    Press Release | September 1, 2022

    Pliant Therapeutics Announces Positive DSMB Safety Review of INTEGRIS-IPF Phase 2a Trial of PLN-74809 at 320 mg Dose in Idiopathic Pulmonary Fibrosis

    Read More

    Press Release | July 26, 2022

    Affini-T Therapeutics Appoints Pioneering T Cell Therapy and KRAS Developer Dirk Nagorsen, M.D., as Chief Medical Officer

    Read More

    Press Release | July 11, 2022

    Pliant Therapeutics Announces Positive Safety and Efficacy Data from Phase 2a INTEGRIS-IPF Clinical Trial of PLN-74809 in Patients with Idiopathic Pulmonary Fibrosis

    Read More